InsidersTradesSigma
Cantel Medical CORP Stock: price and insider trades · United States · SEC (Form 4)
Track the Cantel Medical CORP stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cantel Medical CORP has recorded 45 insider filings. The latest transaction was disclosed on 2 June 2021 (Disposition). Among the most active insiders: Diker Mark N.. Every trade is free.
45
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€470m
30 ops.
Sell Volume
29Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 June 2021
Declarations45 total
59,288 shares@ US$80.5948.5% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075849
1,935 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075860
12,132 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075850
16,036 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075857:0
12,132 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075850:0
13,953 shares@ US$80.5948.9% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075843:0
3,890 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075859:0
41,622 shares@ US$80.5949.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075864:0
59,288 shares@ US$80.5948.5% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075849:0
22,970.431 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075863
57,585 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075839
41,622 shares@ US$80.5949.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075864
7,570 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075852
16,036 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075857
12,216 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075845
4,400 shares0Common Stock, par value $.10 per shareSEC:0001104659-21-075853
3,890 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075859
10,566 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075846
22,970.431 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075863:0
12,216 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075845:0
10,566 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075846:0
4,159 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075840:0
434,505 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075855:0
57,585 shares@ US$80.5950.0% of flowCommon Stock, par value $.10 per shareSEC:0001104659-21-075839:0
4,400 shares0Common Stock, par value $.10 per shareSEC:0001104659-21-075853:0
25 of 45 declarations
About Cantel Medical CORP
Cantel Medical Corp. (ticker: CMD) was a U.S.-based healthcare company focused on infection prevention and medical-device reprocessing. It was historically listed on the NASDAQ before being acquired by STERIS, with the transaction completed in June 2021. For French-speaking investors in France, Belgium and Switzerland, Cantel is best understood as a former listed medtech specialty name whose operating footprint and product know-how were folded into a larger U.S. healthcare platform. The company was founded in 1963 in Little Falls, New Jersey, and built its franchise around products and services designed to reduce infection risk in clinical and life-science settings. Its historical headquarters were in the United States, and over time it expanded through a mix of organic growth and acquisitions. Cantel strengthened its portfolio through deals that added capabilities in endoscopy, water purification, and dental infection-control solutions, giving it a diversified but highly specialized position in healthcare hygiene and reprocessing. Prior to the STERIS acquisition, Cantel reported four operating segments: Medical, Life Sciences, Dental and Dialysis. That structure captured its exposure to healthcare procedures, laboratory environments and other settings where contamination control is mission-critical. Its core offering included medical-device reprocessing systems, disinfectants, detergents, cleaning and disinfection consumables, and water purification and filtration solutions. In endoscopy, in particular, Cantel was recognized for equipment and consumables used to clean and disinfect flexible endoscopes and related reusable devices. From a competitive standpoint, Cantel occupied a defensible niche. Demand was supported by recurring regulatory requirements, patient-safety standards and the constant need for hospitals, clinics and labs to comply with strict hygiene protocols. The business model combined installed equipment, recurring consumables and technical services, which typically creates a relatively resilient revenue base and meaningful customer switching costs. The most important recent corporate event was the company’s integration into STERIS, a U.S. company listed on the NYSE, which completed the acquisition in 2021. As a result, CMD is no longer an independent public stock, but the assets and product lines that once belonged to Cantel continue inside a much larger global sterilization and infection-prevention platform. In market terms, Cantel should therefore be viewed as a former U.S. NASDAQ-listed healthcare specialist whose legacy remains relevant through STERIS’s broader business mix.
